Exhibit 99.1 OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update New York, NY, August 19, 2025 – OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported second quarter 2025 financial results ended June 30, 2025 and provided a business update. Third Quarter 2025 Progress to Date and Future Milestones Progress to Date: 2 ● Reported final EFS data (35% vs. 20%, ...